Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emepronium is a quaternary ammonium compound and small molecule anticholinergic drug, primarily used in urology as an antispasmodic for the treatment of urinary frequency, urge, urge incontinence, polyuria, nocturia, enuresis, and hypertonic bladder states following surgery or radiotherapy. It acts as a muscarinic antagonist by blocking acetylcholine at muscarinic receptors (notably the muscarinic acetylcholine receptor M5), leading to relaxation of bladder muscles. The drug is incompletely absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It is usually administered orally or intramuscularly. Emepronium can cause esophageal ulceration if not taken with sufficient liquids in an upright position[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on emepronium.